Lorlatinib: Phase I/II data

Data from 52 evaluable patients with ALK- or ROS1-positive advanced NSCLC in the dose-escalation Phase I portion of an open-label,

Read the full 203 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE